This quarter is make or break.If someone loses their nerve now, they are not cut out for biotech investment and should stick to blue chips.The product has convinced the US DOD to try it for P2 maybe even P3.That's a good recommendation.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
